Large randomized studies have shown the short-term development of immunity after SARS-CoV-2 vaccination for up to three months. However, it is currently unclear how long this immunity lasts, how good vaccine protection is in the "real world" and especially in the elderly (that is, in practice rather than in studies), and whether immunity after vaccination is comparable to that after infection with the SARS-CoV-2 virus. It is also not known whether vaccinations should be given without testing antibodies.
The aim of the Zurich Corona vaccination study is to investigate the immune response following the vaccines approved in Switzerland in randomly selected and therefore representative samples of individuals. Comparison with the also representative sample of individuals with SARS-CoV-2 infection (ZSAC study E7) will allow comparison of infection- and vaccine-induced immunity.
If, as expected, we will have four vaccines available at the Corona Center of the EBPI, we will thus enroll 800 participants (4 x 100 per age group) in the study.
All participants will be asked to complete an electronic questionnaire at the beginning of the study (baseline; usually the day of the first vaccine dose), and at 3-4 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months after baseline. Questionnaires may be completed before or during (with assistance, if needed) study visits.
